On the clinical usefulness of the free-to-total prostate-specific antigen ratio

S. Ciatto, T. Rubeca, R. Franceschini, C. Trevisiol, M. Confortini, G. Pontenani, C. Lombardi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The free-to-total prostate-specific antigen ratio (F/T PSA) is associated with the presence of prostate cancer and is thus used as an indicator for suspicion of prostate cancer and as a determinant for biopsy. We reviewed a recent retrospective series of 966 consecutive prostate biopsies where F/T PSA was blindly determined and did not influence biopsy indication. We simulated the association of F/T PSA with biopsy outcome and its impact as a biopsy determinant. When adopting an F/T PSA cutoff of 10%, 13%, 16% or 20% among random sextant biopsies in the 4-10 ng/mL total PSA range, the sensitivity was 15%, 37%, 55% and 72% and the specificity 89%, 80%, 64% and 44%, respectively. Using F/T PSA as a biopsy determinant, from 1.7 to 2.6 cancer biopsies would have been delayed to avoid 10 benign biopsies. As this balance is not acceptable, F/T PSA has no role as a biopsy indicator and its clinical use is questionable.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalInternational Journal of Biological Markers
Volume21
Issue number1
Publication statusPublished - Jan 2006

Fingerprint

Biopsy
Prostate-Specific Antigen
Sextants
Prostatic Neoplasms
Free Association
Prostate

Keywords

  • F/T PSA ratio
  • Prostate cancer
  • PSA

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Ciatto, S., Rubeca, T., Franceschini, R., Trevisiol, C., Confortini, M., Pontenani, G., & Lombardi, C. (2006). On the clinical usefulness of the free-to-total prostate-specific antigen ratio. International Journal of Biological Markers, 21(1), 1-5.

On the clinical usefulness of the free-to-total prostate-specific antigen ratio. / Ciatto, S.; Rubeca, T.; Franceschini, R.; Trevisiol, C.; Confortini, M.; Pontenani, G.; Lombardi, C.

In: International Journal of Biological Markers, Vol. 21, No. 1, 01.2006, p. 1-5.

Research output: Contribution to journalArticle

Ciatto, S, Rubeca, T, Franceschini, R, Trevisiol, C, Confortini, M, Pontenani, G & Lombardi, C 2006, 'On the clinical usefulness of the free-to-total prostate-specific antigen ratio', International Journal of Biological Markers, vol. 21, no. 1, pp. 1-5.
Ciatto S, Rubeca T, Franceschini R, Trevisiol C, Confortini M, Pontenani G et al. On the clinical usefulness of the free-to-total prostate-specific antigen ratio. International Journal of Biological Markers. 2006 Jan;21(1):1-5.
Ciatto, S. ; Rubeca, T. ; Franceschini, R. ; Trevisiol, C. ; Confortini, M. ; Pontenani, G. ; Lombardi, C. / On the clinical usefulness of the free-to-total prostate-specific antigen ratio. In: International Journal of Biological Markers. 2006 ; Vol. 21, No. 1. pp. 1-5.
@article{e669ebe6679f41a685145bbe5475a1e6,
title = "On the clinical usefulness of the free-to-total prostate-specific antigen ratio",
abstract = "The free-to-total prostate-specific antigen ratio (F/T PSA) is associated with the presence of prostate cancer and is thus used as an indicator for suspicion of prostate cancer and as a determinant for biopsy. We reviewed a recent retrospective series of 966 consecutive prostate biopsies where F/T PSA was blindly determined and did not influence biopsy indication. We simulated the association of F/T PSA with biopsy outcome and its impact as a biopsy determinant. When adopting an F/T PSA cutoff of 10{\%}, 13{\%}, 16{\%} or 20{\%} among random sextant biopsies in the 4-10 ng/mL total PSA range, the sensitivity was 15{\%}, 37{\%}, 55{\%} and 72{\%} and the specificity 89{\%}, 80{\%}, 64{\%} and 44{\%}, respectively. Using F/T PSA as a biopsy determinant, from 1.7 to 2.6 cancer biopsies would have been delayed to avoid 10 benign biopsies. As this balance is not acceptable, F/T PSA has no role as a biopsy indicator and its clinical use is questionable.",
keywords = "F/T PSA ratio, Prostate cancer, PSA",
author = "S. Ciatto and T. Rubeca and R. Franceschini and C. Trevisiol and M. Confortini and G. Pontenani and C. Lombardi",
year = "2006",
month = "1",
language = "English",
volume = "21",
pages = "1--5",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "1",

}

TY - JOUR

T1 - On the clinical usefulness of the free-to-total prostate-specific antigen ratio

AU - Ciatto, S.

AU - Rubeca, T.

AU - Franceschini, R.

AU - Trevisiol, C.

AU - Confortini, M.

AU - Pontenani, G.

AU - Lombardi, C.

PY - 2006/1

Y1 - 2006/1

N2 - The free-to-total prostate-specific antigen ratio (F/T PSA) is associated with the presence of prostate cancer and is thus used as an indicator for suspicion of prostate cancer and as a determinant for biopsy. We reviewed a recent retrospective series of 966 consecutive prostate biopsies where F/T PSA was blindly determined and did not influence biopsy indication. We simulated the association of F/T PSA with biopsy outcome and its impact as a biopsy determinant. When adopting an F/T PSA cutoff of 10%, 13%, 16% or 20% among random sextant biopsies in the 4-10 ng/mL total PSA range, the sensitivity was 15%, 37%, 55% and 72% and the specificity 89%, 80%, 64% and 44%, respectively. Using F/T PSA as a biopsy determinant, from 1.7 to 2.6 cancer biopsies would have been delayed to avoid 10 benign biopsies. As this balance is not acceptable, F/T PSA has no role as a biopsy indicator and its clinical use is questionable.

AB - The free-to-total prostate-specific antigen ratio (F/T PSA) is associated with the presence of prostate cancer and is thus used as an indicator for suspicion of prostate cancer and as a determinant for biopsy. We reviewed a recent retrospective series of 966 consecutive prostate biopsies where F/T PSA was blindly determined and did not influence biopsy indication. We simulated the association of F/T PSA with biopsy outcome and its impact as a biopsy determinant. When adopting an F/T PSA cutoff of 10%, 13%, 16% or 20% among random sextant biopsies in the 4-10 ng/mL total PSA range, the sensitivity was 15%, 37%, 55% and 72% and the specificity 89%, 80%, 64% and 44%, respectively. Using F/T PSA as a biopsy determinant, from 1.7 to 2.6 cancer biopsies would have been delayed to avoid 10 benign biopsies. As this balance is not acceptable, F/T PSA has no role as a biopsy indicator and its clinical use is questionable.

KW - F/T PSA ratio

KW - Prostate cancer

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=33646172567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646172567&partnerID=8YFLogxK

M3 - Article

C2 - 16711507

AN - SCOPUS:33646172567

VL - 21

SP - 1

EP - 5

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 1

ER -